Clinical trials have firmly established that ALK TKIs are safe, well tolerated, and effective; these findings reveal that their impact in a real-world setting is just as profound. The availability and use of ALK TKI therapies contribute to the impressive gains in survival experienced by contemporary patients with ALK-rearranged disease, rendering patients with this oncodriven form of NSCLC among the longest surviving patients with lung cancer. READ ARTICLE
Journal of Thoracic Oncology, Clinical and Research Reports DOI:10.1016/j.jtocrr.2021.100157
Authors: Amanda J. W. Gibson, Adrian Box, Michelle L. Dean, Anifat A. Elegbede, Desiree Hao, Randeep Sangha, D. Gwyn Bebb
